Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

Configure the table properties Dosage and administration In the Phase 3 VALOR clinical trial, brepocitinib was administered orally once daily at a dose of 15 mg or 30 mg for 52 weeks. Place in...

In the latest episode of the “Pharmacy Friends” podcast, hear more from Prime Therapeutics experts about how oral glucagon-like peptide-1 (GLP-1) agonist medications may transform the treatment...

denecimig (Mim8) - Hematologic The Deep dive section features an analysis for select pipeline drugs that are expected to be FDA-approved in the upcoming quarters. Selected agents are expected to...

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

New report details the latest on GLP-1s